Creso Pharma shares surge 16% on CannaQix® and the SwissVit™ news
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Shares in Creso Pharma (ASX: CPH) hit a high of 51 cents on Wednesday morning after the company announced that it was on track to launch its proprietary CannaQix® human health nutraceutical product, which has applications in the area of anxiety and stress in the first or second quarter of 2018.
Furthermore line extensions in the area of bone metabolism are due for launch in the second quarter of 2019. Yesterday morning’s re-rating represented an increase of 16% compared with the previous day’s close of 44 cents.
Those considering this stock shouldn’t make assumptions regarding future sales, nor should they base investment decisions on performances to date. Those considering this stock should seek independent financial advice.
Management also confirmed that the importation of the Swiss medical cannabis products into Asia Pacific and Latin America was progressing as planned and that the company was looking to introduce a range of proprietary SwissVitTM premium nutraceutical products into the Asia-Pacific region and Australia.
On this note, the company is in negotiations with potential commercial partners and expects to formally launch the products in Australia and across the Asia-Pacific region in 2018. The latter represents an attractive market opportunity for CPH with demand for wellness and prevention health products increasing among well-informed consumers as health care cost containment efforts rise.
Discussing these developments, CPH Chief Executive and co-founder Doctor Miri Halperin Wernli said, “We are looking forward to making the Swiss medicinal cannabis products available in the Asia-Pacific region and Latin America, as well as progressing our negotiations with our commercial partners for our innovative SwissVitTM range of products in collaboration with iNNutriGEL over the coming weeks, with an expected launch in Australia and the Asia-Pacific region in 2018”.
SwissVitTM targeting $40 billion market
CPH referred to data from research group Euromonitor in noting that the Asia-Pacific market for vitamins and dietary supplement sales is larger than the US and generated more than US$40 billion in sales in 2016.
According to this source, China is the largest vitamin and dietary supplement in the region, accounting for 45% of total retail value, and it is expected to grow at a compound annual rate of 10% between 2016 and 2021.
CPH plans to launch various SwissVitTM nutraceutical products specifically formulated to target a number of health-related areas including eye health, immunity, bones and joints, oral iron supplementation and digestions.
The innovative patented delivery technology uses buccal absorption of the active molecules (through the blood vessels on the inside of the mouth), offering high bioavailability and absorption of the vitamins.
Management is of the view that the innovative and proprietary characteristics of the delivery technology and the specific vitamin mixes of the products will make Swiss nutraceuticals well suited to the Asia-Pacific region.
Creso on track to introduce animal feed products in September 2017
CPH also announced today that following the registration of hemp extract in the European Feed Material Register, the company was on track to launch its proprietary formulated hemp based complementary feed products for companion and zoo animals in September 2017.
The registered products, anibidiol® 2.5 for small companion animals and anibidiol® 80 for large companion animals and zoo animals will be introduced in Switzerland and Europe, followed by South Africa and selected countries in the Gulf Region and Latin America.
General Information Only
This material has been prepared by StocksDigital. StocksDigital is an authorised representative (CAR 000433913) of 62 Consulting Pty Limited (ABN 88 664 809 303) (AFSL 548573).
This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by 62C, StocksDigital, any of their related body corporates or any other person. To the maximum extent possible, 62C, StocksDigital, their related body corporates or any other person do not accept any liability for any statement in this material.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
